Enzalutamida. Desarrollo futuro - page 13

Menor pérdida de masa ósea que con agonistas

Tendencia a sarcopenia: Más grasa y menos masa muscular pero menos que con agonistas o

bicalutamida

No cambios en hábito sexual

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,3,4,5,6,7,8,9,10,11,12 14,15,16,17,18,19,20,21,22,23,...34